+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ovarian Cancer Therapeutics - Market Analysis, Trends, and Forecasts

  • ID: 4845798
  • Report
  • October 2019
  • Region: Global
  • 145 pages
  • Global Industry Analysts, Inc
1 of 3

FEATURED COMPANIES

  • Amgen
  • Astrazeneca Plc
  • Chugai Pharmaceutical
  • Clovis Oncology
  • Eli Lilly and Company
  • Genentech, Inc.
  • MORE
The Ovarian Cancer Therapeutics market worldwide is projected to grow by US$4.7 Billion, driven by a compounded growth of 22.1%. PARP Inhibitors, one of the segments analyzed and sized in this study, displays the potential to grow at over 23.4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$3.7 Billion by the year 2025, PARP Inhibitors will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 20.4% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$201.6 Million to the region's size and clout in the next 5 to 6 years. Over US$171.5 Million worth of projected demand in the region will come from the rest of the European markets. In Japan, PARP Inhibitors will reach a market size of US$189.1 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 26.3% over the next couple of years and add approximately US$1.1 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:
  • AstraZeneca PLC
  • Clovis Oncology
  • Genentech, Inc.
  • Tesaro, Inc.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen
  • Astrazeneca Plc
  • Chugai Pharmaceutical
  • Clovis Oncology
  • Eli Lilly and Company
  • Genentech, Inc.
  • MORE

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Global Competitor Market Shares

Ovarian Cancer Therapeutics Competitor Market Share Scenario Worldwide (in %): 2019 & 2028

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: Ovarian Cancer Therapeutics Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025

TABLE 2: Ovarian Cancer Therapeutics Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017

TABLE 3: Ovarian Cancer Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025

TABLE 4: PARP Inhibitors (Therapeutic Class) World Market by Region/Country in US$ Thousand: 2018 to 2025

TABLE 5: PARP Inhibitors (Therapeutic Class) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017

TABLE 6: PARP Inhibitors (Therapeutic Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025

TABLE 7: Angiogenesis Inhibitors (Therapeutic Class) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025

TABLE 8: Angiogenesis Inhibitors (Therapeutic Class) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017

TABLE 9: Angiogenesis Inhibitors (Therapeutic Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025

TABLE 10: PD-L1 Inhibitors (Therapeutic Class) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025

TABLE 11: PD-L1 Inhibitors (Therapeutic Class) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017

TABLE 12: PD-L1 Inhibitors (Therapeutic Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

Market Facts & Figures

US Ovarian Cancer Therapeutics Market Share (in %) by Company: 2019 & 2025

TABLE 13: United States Ovarian Cancer Therapeutics Market Estimates and Projections in US$ Thousand by Therapeutic Class: 2018 to 2025

TABLE 14: Ovarian Cancer Therapeutics Market in the United States by Therapeutic Class: A Historic Review in US$ Thousand for 2009-2017

TABLE 15: United States Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

CANADA

TABLE 16: Canadian Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Therapeutic Class: 2018 to 2025

TABLE 17: Canadian Ovarian Cancer Therapeutics Historic Market Review by Therapeutic Class in US$ Thousand: 2009-2017

TABLE 18: Ovarian Cancer Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025

JAPAN

TABLE 19: Japanese Market for Ovarian Cancer Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 20: Ovarian Cancer Therapeutics Market in Japan: Historic Sales Analysis in US$ Thousand by Therapeutic Class for the Period 2009-2017

TABLE 21: Japanese Ovarian Cancer Therapeutics Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025

CHINA

TABLE 22: Chinese Ovarian Cancer Therapeutics Market Growth Prospects in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 23: Ovarian Cancer Therapeutics Historic Market Analysis in China in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 24: Chinese Ovarian Cancer Therapeutics Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

EUROPE

Market Facts & Figures

European Ovarian Cancer Therapeutics Market: Competitor Market Share Scenario (in %) for 2019 & 2025

TABLE 25: European Ovarian Cancer Therapeutics Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025

TABLE 26: Ovarian Cancer Therapeutics Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017

TABLE 27: European Ovarian Cancer Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025

TABLE 28: European Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Therapeutic Class: 2018-2025

TABLE 29: Ovarian Cancer Therapeutics Market in Europe in US$ Thousand by Therapeutic Class: A Historic Review for the Period 2009-2017

TABLE 30: European Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

FRANCE

TABLE 31: Ovarian Cancer Therapeutics Market in France by Therapeutic Class: Estimates and Projections in US$ Thousand for the Period 2018-2025

TABLE 32: French Ovarian Cancer Therapeutics Historic Market Scenario in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 33: French Ovarian Cancer Therapeutics Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025

GERMANY

TABLE 34: Ovarian Cancer Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 35: German Ovarian Cancer Therapeutics Historic Market Analysis in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 36: German Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

ITALY

TABLE 37: Italian Ovarian Cancer Therapeutics Market Growth Prospects in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 38: Ovarian Cancer Therapeutics Historic Market Analysis in Italy in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 39: Italian Ovarian Cancer Therapeutics Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED KINGDOM

TABLE 40: United Kingdom Market for Ovarian Cancer Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 41: Ovarian Cancer Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Therapeutic Class for the Period 2009-2017

TABLE 42: United Kingdom Ovarian Cancer Therapeutics Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025

SPAIN

TABLE 43: Spanish Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Therapeutic Class: 2018 to 2025

TABLE 44: Spanish Ovarian Cancer Therapeutics Historic Market Review by Therapeutic Class in US$ Thousand: 2009-2017

TABLE 45: Ovarian Cancer Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025

RUSSIA

TABLE 46: Russian Ovarian Cancer Therapeutics Market Estimates and Projections in US$ Thousand by Therapeutic Class: 2018 to 2025

TABLE 47: Ovarian Cancer Therapeutics Market in Russia by Therapeutic Class: A Historic Review in US$ Thousand for 2009-2017

TABLE 48: Russian Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

REST OF EUROPE

TABLE 49: Rest of Europe Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Therapeutic Class: 2018-2025

TABLE 50: Ovarian Cancer Therapeutics Market in Rest of Europe in US$ Thousand by Therapeutic Class: A Historic Review for the Period 2009-2017

TABLE 51: Rest of Europe Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

ASIA-PACIFIC

TABLE 52: Asia-Pacific Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025

TABLE 53: Ovarian Cancer Therapeutics Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017

TABLE 54: Asia-Pacific Ovarian Cancer Therapeutics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025

TABLE 55: Ovarian Cancer Therapeutics Market in Asia-Pacific by Therapeutic Class: Estimates and Projections in US$ Thousand for the Period 2018-2025

TABLE 56: Asia-Pacific Ovarian Cancer Therapeutics Historic Market Scenario in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 57: Asia-Pacific Ovarian Cancer Therapeutics Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025

AUSTRALIA

TABLE 58: Ovarian Cancer Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 59: Australian Ovarian Cancer Therapeutics Historic Market Analysis in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 60: Australian Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

INDIA

TABLE 61: Indian Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Therapeutic Class: 2018 to 2025

TABLE 62: Indian Ovarian Cancer Therapeutics Historic Market Review by Therapeutic Class in US$ Thousand: 2009-2017

TABLE 63: Ovarian Cancer Therapeutics Market in India: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025

SOUTH KOREA

TABLE 64: Ovarian Cancer Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 65: South Korean Ovarian Cancer Therapeutics Historic Market Analysis in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 66: Ovarian Cancer Therapeutics Market Share Distribution in South Korea by Therapeutic Class: 2009 VS 2019 VS 2025

REST OF ASIA-PACIFIC

TABLE 67: Rest of Asia-Pacific Market for Ovarian Cancer Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 68: Ovarian Cancer Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Therapeutic Class for the Period 2009-2017

TABLE 69: Rest of Asia-Pacific Ovarian Cancer Therapeutics Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025

LATIN AMERICA

TABLE 70: Latin American Ovarian Cancer Therapeutics Market Trends by Region/Country in US$ Thousand: 2018-2025

TABLE 71: Ovarian Cancer Therapeutics Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017

TABLE 72: Latin American Ovarian Cancer Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025

TABLE 73: Latin American Ovarian Cancer Therapeutics Market Growth Prospects in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 74: Ovarian Cancer Therapeutics Historic Market Analysis in Latin America in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 75: Latin American Ovarian Cancer Therapeutics Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

ARGENTINA

TABLE 76: Argentinean Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Therapeutic Class: 2018-2025

TABLE 77: Ovarian Cancer Therapeutics Market in Argentina in US$ Thousand by Therapeutic Class: A Historic Review for the Period 2009-2017

TABLE 78: Argentinean Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

BRAZIL

TABLE 79: Ovarian Cancer Therapeutics Market in Brazil by Therapeutic Class: Estimates and Projections in US$ Thousand for the Period 2018-2025

TABLE 80: Brazilian Ovarian Cancer Therapeutics Historic Market Scenario in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 81: Brazilian Ovarian Cancer Therapeutics Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025

MEXICO

TABLE 82: Ovarian Cancer Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 83: Mexican Ovarian Cancer Therapeutics Historic Market Analysis in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 84: Mexican Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

REST OF LATIN AMERICA

TABLE 85: Rest of Latin America Ovarian Cancer Therapeutics Market Estimates and Projections in US$ Thousand by Therapeutic Class: 2018 to 2025

TABLE 86: Ovarian Cancer Therapeutics Market in Rest of Latin America by Therapeutic Class: A Historic Review in US$ Thousand for 2009-2017

TABLE 87: Rest of Latin America Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

MIDDLE EAST

TABLE 88: The Middle East Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025

TABLE 89: Ovarian Cancer Therapeutics Market in the Middle East by Region/Country in US$ Thousand: 2009-2017

TABLE 90: The Middle East Ovarian Cancer Therapeutics Market Share Breakdown by Region/Country: 2009, 2019, and 2025

TABLE 91: The Middle East Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Therapeutic Class: 2018 to 2025

TABLE 92: The Middle East Ovarian Cancer Therapeutics Historic Market by Therapeutic Class in US$ Thousand: 2009-2017

TABLE 93: Ovarian Cancer Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025

IRAN

TABLE 94: Iranian Market for Ovarian Cancer Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 95: Ovarian Cancer Therapeutics Market in Iran: Historic Sales Analysis in US$ Thousand by Therapeutic Class for the Period 2009-2017

TABLE 96: Iranian Ovarian Cancer Therapeutics Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025

ISRAEL

TABLE 97: Israeli Ovarian Cancer Therapeutics Market Estimates and Forecasts in US$ Thousand by Therapeutic Class: 2018-2025

TABLE 98: Ovarian Cancer Therapeutics Market in Israel in US$ Thousand by Therapeutic Class: A Historic Review for the Period 2009-2017

TABLE 99: Israeli Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

SAUDI ARABIA

TABLE 100: Saudi Arabian Ovarian Cancer Therapeutics Market Growth Prospects in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 101: Ovarian Cancer Therapeutics Historic Market Analysis in Saudi Arabia in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 102: Saudi Arabian Ovarian Cancer Therapeutics Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED ARAB EMIRATES

TABLE 103: Ovarian Cancer Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 104: United Arab Emirates Ovarian Cancer Therapeutics Historic Market Analysis in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 105: Ovarian Cancer Therapeutics Market Share Distribution in United Arab Emirates by Therapeutic Class: 2009 VS 2019 VS 2025

REST OF MIDDLE EAST

TABLE 106: Ovarian Cancer Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Therapeutic Class for the Period 2018-2025

TABLE 107: Rest of Middle East Ovarian Cancer Therapeutics Historic Market Analysis in US$ Thousand by Therapeutic Class: 2009-2017

TABLE 108: Rest of Middle East Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

AFRICA

TABLE 109: African Ovarian Cancer Therapeutics Market Estimates and Projections in US$ Thousand by Therapeutic Class: 2018 to 2025

TABLE 110: Ovarian Cancer Therapeutics Market in Africa by Therapeutic Class: A Historic Review in US$ Thousand for 2009-2017

TABLE 111: African Ovarian Cancer Therapeutics Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025

IV. COMPETITION

TESARO, INC.

GENENTECH, INC.

ASTRAZENECA PLC

CLOVIS ONCOLOGY

AMGEN

BRISTOL-MYERS SQUIBB COMPANY

CHUGAI PHARMACEUTICAL

DR. REDDY'S LABORATORIES LTD.

ELI LILLY AND COMPANY

GLAXOSMITHKLINE PLC

MEDIMMUNE

ROCHE DIAGNOSTICS CORPORATION

V. CURATED RESEARCH

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Tesaro, Inc.
  • Genentech, Inc.
  • Astrazeneca Plc
  • Clovis Oncology
  • Amgen
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Glaxosmithkline Plc
  • Medimmune
  • Roche Diagnostics Corporation
Note: Product cover images may vary from those shown
Adroll
adroll